Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 6/20 | 0.35 |
| ▸ | CPT1B | Q92523 | 6/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.32 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492761 | 1.00 | KDM4E (0.35) | KDM4EMAPTCPT1ACPT1BLRRK2 | |
| SCHEMBL4492148 | 0.95 | KDM4E (0.34) | KDM4EMAPTCPT1ACPT1BLRRK2 | |
| SCHEMBL4492150 | 0.95 | KDM4E (0.34) | KDM4EMAPTCPT1ACPT1BLRRK2 | |
| SCHEMBL225783 | 0.92 | FFAR1 (0.35) | LRRK2F10NR1H4CSF1R | |
| SCHEMBL225782 | 0.92 | FFAR1 (0.35) | LRRK2F10NR1H4CSF1R | |
| SCHEMBL4505219 | 0.92 | MCHR1 (0.33) | KDM4EMAPTLRRK2NR1H4 | |
| SCHEMBL4505215 | 0.92 | MCHR1 (0.33) | KDM4EMAPTLRRK2NR1H4 | |
| SCHEMBL4504795 | 0.91 | KDM4E (0.36) | KDM4EMAPTCPT1ACPT1BLRRK2 | |
| SCHEMBL4504799 | 0.91 | KDM4E (0.36) | KDM4EMAPTCPT1ACPT1BLRRK2 | |
| SCHEMBL4560167 | 0.91 | LRRK2 (0.36) | KDM4EMAPTLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | KDM4E 1648/4885MAPT 545/4885CPT1A 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.